Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Irinotecan pharmacogenetics

This chapter reviews recent progress in irinotecan pharmacogenetics, including novel functional genetic variations and the haplotype structures of UGTlAs, with particular focus on the cumulative data showing the clinical relevance of UGTIAI... [Pg.269]

Sai K, Kaniwa N, Itoda M et al. Haplotype analysis of ABCBl/MDRl blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003 13 741-757. [Pg.286]

Hoskins JM, Marcuello E, Altes A, et al. Irinotecan pharmacogenetics influence ofpharma-codynamic genes. Clin Cancer Res 2008 14(6) 1788-96. [Pg.28]

McLeod HL, Watters JW. Irinotecan pharmacogenetics is it time to intervene J Clin Oncol 2004 22(8) 1356-9. [Pg.81]

Irinotecan and UCT1A1 Pharmacogenetics 14.2.3.1 Clinical Use and Toxicity of Irinotecan... [Pg.292]

Ando, Y., Saka, H., Ando, M., et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity a pharmacogenetic analysis. Cancer Res. 60, 6921-6926. [Pg.412]

Key Words UGTIAI UGTIA7 UGTIA9 pharmacogenetics irinotecan SN-38 Haplotype... [Pg.268]

Minami H, Sai K, Saeki M et al. Irinotecan pharmacokineitcs/pharmacodynamics and UGTIA genetic polymorphisms in Japanese Roles ofUGTlAl 6 and 28. Pharmacogenet Genomics 2007 17 497-504. [Pg.286]

Kitagawa C, Ando M, Ando Y et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase lAl gene and irinotecan toxicity. Pharmacogenet Genomics 2005 15 35 1. [Pg.286]

Xiang X, Jada SR, Li HH et al. Pharmacogenetics of SLCOIBI gene and the impact of lb and 15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 2006 16 683-691. [Pg.286]

Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan clinical perspectives on the utility of genotyping. Pharmacogenomics 2006 7(8) 1211-1221. [Pg.115]

Innocent E, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents Lessons form amonafide and irinotecan. Drug Met. Disp. 2001 29 596-600. [Pg.1933]

Pharmacogenetic analysis of interindividual irinotecan (CPT-11) pharmacokinetics (PK) variability evidence for a functional variant of ABCC2. Journal of Clinical Oncology. 22. 2010. [Pg.346]

See other pages where Irinotecan pharmacogenetics is mentioned: [Pg.268]    [Pg.269]    [Pg.271]    [Pg.281]    [Pg.283]    [Pg.142]    [Pg.145]    [Pg.226]    [Pg.268]    [Pg.269]    [Pg.271]    [Pg.281]    [Pg.283]    [Pg.142]    [Pg.145]    [Pg.226]    [Pg.25]    [Pg.59]    [Pg.269]    [Pg.271]    [Pg.277]    [Pg.279]    [Pg.281]    [Pg.283]    [Pg.283]    [Pg.285]    [Pg.356]    [Pg.259]    [Pg.429]    [Pg.734]    [Pg.226]    [Pg.3455]    [Pg.733]    [Pg.1611]    [Pg.115]    [Pg.266]    [Pg.332]    [Pg.70]    [Pg.81]    [Pg.2408]    [Pg.100]   
See also in sourсe #XX -- [ Pg.886 ]



SEARCH



Irinotecan

Pharmacogenetic

Pharmacogenetics

© 2024 chempedia.info